Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccine in Nonimmunocompromised Children and Adolescents
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
MMWR. Morbidity and Mortality Weekly Report
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022
MMWR Morb. Mortal. Wkly. Rep. 2022 Mar 04;71(9)352-358, NP Klein, MS Stockwell, M Demarco, M Gaglani, AB Kharbanda, SA Irving, S Rao, SJ Grannis, K Dascomb, K Murthy, EA Rowley, AF Dalton, MB DeSilva, BE Dixon, K Natarajan, E Stenehjem, AL Naleway, N Lewis, TC Ong, P Patel, D Konatham, PJ Embi, SE Reese, J Han, N Grisel, K Goddard, MA Barron, M Dickerson, IC Liao, WF Fadel, DH Yang, J Arndorfer, B Fireman, EP Griggs, NR Valvi, C Hallowell, O Zerbo, S Reynolds, J Ferdinands, MH Wondimu, J Williams, CH Bozio, R Link-Gelles, E Azziz-Baumgartner, SJ Schrag, MG Thompson, JR VeraniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.